EUVIMEDEUVIMED entdecken
Kommentar

To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

S M Yin, D L Li

Cell Stem Cell · 2024

DOI: 10.1016/j.stem.2024.10.009 ↗

Kurz gefasst

Kommentar in der Zeitschrift Cell Stem Cell, 2024. Verfasst von S M Yin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences…. Hauptthemen laut MEDLINE: Immunotherapy, Epitopes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyEpitopesHumansLeukemia, Myeloid, AcuteHematopoietic Stem CellsGene Editing

Substanzen

Epitopes

Autor:innen und Institutionen

  • Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai,…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yin, S. M., & Li, D. L. (2024). To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy. Cell Stem Cell. https://doi.org/10.1016/j.stem.2024.10.009

Vancouver

Yin SM, Li DL. To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy. Cell Stem Cell. 2024. doi:10.1016/j.stem.2024.10.009

BibTeX
@article{Yin2024,
  author = {Yin, S M and Li, D L},
  title = {To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy},
  journal = {Cell Stem Cell},
  year = {2024},
  doi = {10.1016/j.stem.2024.10.009}
}
Kostenlos starten →